… of allosteric inhibitors and other kinases inhibitors can … SHP2 inhibitors and revisited the
SHP2-targeted anticancer strategies, and combination therapies with other PTK inhibitors …

… protein could be a novel approach to enhance other targeted therapies for human cancers.
… -molecule inhibitor targeting the SH2 domains of SHP2 was reported. Direct targeting the …

… and functions of SHP2, and briefly review the development of SHP2 inhibitors. Importantly, …
using SHP2 inhibitors. We also discuss the future clinical applications of SHP2 inhibitors, …

… A potent, highly specific inhibitor targeting SHP2, SHP099, … would inhibit signals from RTKs
activated following MEK inhibition … Our results suggest that SHP2 inhibition could provide a …

… Combining SHP2 inhibitors targeting different binding sites is another promising strategy,
which may exhibit synergistic effect on SHP2 inhibition and overcome drug resistance (Figure 8…

… targeted therapies that include an inhibitor of SHP2, a protein tyrosine phosphatase. SHP2
… multiple mechanisms: dephosphorylation of inhibitory tyrosine phosphorylation on positive …

… in these complex signaling pathways will help us improve targeted therapy for SHP2, as well
as combination treatments, by identifying additional druggable molecules. The contribution …

… The collective preclinical data and these early clinical findings support the continued
combination testing of current targeted therapies together with allosteric SHP2 inhibitors in RAS-…

… inhibit its activity, we sought to address the hypothesis that SHP2 will be an effective therapeutic
target for … targeted therapies, our studies strongly support development of this combined …

… SHP2 allosteric inhibitors … SHP2 and highlights the vital roles of SHP2 in T lymphocytes,
macrophages and cancer cells. It also summarizes the current development of SHP2 inhibitors …